Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of EE/LNG with Zibotentan
NCT05505162Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Aug 2022
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of zibotentan in chronic kidney disease (CKD), sponsored by AstraZeneca. Primary endpoints: Area under plasma concentration time curve from zero to infinity at Day 15, Area under the plasma concentration curve from zero to the last quantifiable concentration at Day 15 and 5 more. Started Aug 2022; status: completed.
02
Drugs
zibotentan
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT05505162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05505162.